1. Home
  2. CNS vs AKRO Comparison

CNS vs AKRO Comparison

Compare CNS & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CNS
  • AKRO
  • Stock Information
  • Founded
  • CNS 1986
  • AKRO 2017
  • Country
  • CNS United States
  • AKRO United States
  • Employees
  • CNS N/A
  • AKRO N/A
  • Industry
  • CNS Investment Managers
  • AKRO Biotechnology: Pharmaceutical Preparations
  • Sector
  • CNS Finance
  • AKRO Health Care
  • Exchange
  • CNS Nasdaq
  • AKRO Nasdaq
  • Market Cap
  • CNS 4.0B
  • AKRO 3.9B
  • IPO Year
  • CNS 2004
  • AKRO 2019
  • Fundamental
  • Price
  • CNS $72.26
  • AKRO $48.37
  • Analyst Decision
  • CNS Hold
  • AKRO Strong Buy
  • Analyst Count
  • CNS 3
  • AKRO 6
  • Target Price
  • CNS $82.00
  • AKRO $82.50
  • AVG Volume (30 Days)
  • CNS 234.3K
  • AKRO 888.5K
  • Earning Date
  • CNS 07-17-2025
  • AKRO 08-08-2025
  • Dividend Yield
  • CNS 3.44%
  • AKRO N/A
  • EPS Growth
  • CNS 23.33
  • AKRO N/A
  • EPS
  • CNS 3.15
  • AKRO N/A
  • Revenue
  • CNS $543,579,000.00
  • AKRO N/A
  • Revenue This Year
  • CNS $7.32
  • AKRO N/A
  • Revenue Next Year
  • CNS $8.15
  • AKRO N/A
  • P/E Ratio
  • CNS $22.93
  • AKRO N/A
  • Revenue Growth
  • CNS 11.54
  • AKRO N/A
  • 52 Week Low
  • CNS $68.99
  • AKRO $21.34
  • 52 Week High
  • CNS $110.67
  • AKRO $58.40
  • Technical
  • Relative Strength Index (RSI)
  • CNS 39.01
  • AKRO 39.94
  • Support Level
  • CNS $74.03
  • AKRO $46.92
  • Resistance Level
  • CNS $75.63
  • AKRO $49.36
  • Average True Range (ATR)
  • CNS 2.29
  • AKRO 1.89
  • MACD
  • CNS -0.24
  • AKRO -0.50
  • Stochastic Oscillator
  • CNS 10.70
  • AKRO 17.97

About CNS Cohen & Steers Inc

Cohen & Steers is a niche asset manager concentrating on real estate securities. The firm invests mainly in the equity shares of real estate investment trusts, with holdings in domestic and international real estate securities accounting for close to two thirds of its $79.3 billion in managed assets at the end of January 2024. Cohen & Steers also manages portfolios dedicated to preferred securities, utilities stocks, and other high-yield offerings. The firm's distribution is balanced among its closed-end funds, open-end funds, and institutional accounts. During the past four calendar quarters, the company garnered 42% (27%) of its managed assets (base management fees) from institutional clients, 45% (52%) from open-end funds, and 13% (21%) from closed-end funds.

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

Share on Social Networks: